{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:35:09Z","timestamp":1793579709732,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35 CA197731-01"],"award-info":[{"award-number":["R35 CA197731-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jtho.2024.11.022","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T01:55:47Z","timestamp":1732586147000},"page":"331-344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer"],"prefix":"10.1016","volume":"20","author":[{"given":"Aslamuzzaman","family":"Kazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitesh","family":"Vasiyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deblina","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipankar","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachit D.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh","family":"Vudatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Trevino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said M.","family":"Sebti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2024.11.022_bib2","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.3390\/cancers15143710","article-title":"Current challenges and future advances in lung cancer: genetics, instrumental diagnosis and treatment","volume":"15","author":"Vicidomini","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2024.11.022_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2024.11.022_bib4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cell.2007.05.018","article-title":"GEFs and GAPs: critical elements in the control of small G proteins","volume":"129","author":"Bos","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2024.11.022_bib5","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1146\/annurev.bi.56.070187.004023","article-title":"ras genes","volume":"56","author":"Barbacid","year":"1987","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.jtho.2024.11.022_bib6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2024.11.022_bib7","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41568-018-0076-6","article-title":"A\u00a0model for RAS mutation patterns in cancers: finding the sweet spot","volume":"18","author":"Li","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2024.11.022_bib8","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jtho.2024.11.022_bib9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: weaving a tumorigenic web","volume":"11","author":"Pylayeva-Gupta","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2024.11.022_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41416-019-0499-1","article-title":"Direct Ras G12C inhibitors: crossing the rubicon","volume":"121","author":"Lindsay","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2024.11.022_bib12","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1111\/1759-7714.13538","article-title":"KRAS oncogene may be another target conquered in non-small cell lung cancer (NSCLC)","volume":"11","author":"Chen","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtho.2024.11.022_bib13","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.11.022_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2024.11.022_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.11.022_bib16","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.11.022_bib17","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.11.022_bib18","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical acquired resistance to KRASG12C inhibition through a novel KRAS Switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2024.11.022_bib19","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.11.022_bib20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.11.022_bib21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(23)00616-2","article-title":"The fate of sotorasib: a regulatory failure potentially harming patients","volume":"25","author":"Ranganathan","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2024.11.022_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejca.2021.10.003","article-title":"HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2","volume":"159","author":"Ho","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2024.11.022_bib23","author":"Singh"},{"key":"10.1016\/j.jtho.2024.11.022_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231160141","article-title":"Direct GDP-KRASG12C inhibitors and mechanisms of resistance: the tip of the iceberg","volume":"15","author":"Rosen","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jtho.2024.11.022_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110993","article-title":"KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy","volume":"39","author":"Ryan","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.jtho.2024.11.022_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/science.adk0775","article-title":"Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers","volume":"384","author":"Klomp","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.jtho.2024.11.022_bib27","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrc3151","article-title":"Targeting protein prenylation for cancer therapy","volume":"11","author":"Berndt","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2024.11.022_bib28","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-18-3399","article-title":"Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors","volume":"25","author":"Kazi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.11.022_bib29","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/nprot.2011.387","article-title":"Measurement of protein farnesylation and geranylgeranylation in\u00a0vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors","volume":"6","author":"Berndt","year":"2011","journal-title":"Nat Protoc"},{"key":"10.1016\/j.jtho.2024.11.022_bib30","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0092-8674(91)90460-G","article-title":"Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit","volume":"65","author":"Seabra","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2024.11.022_bib31","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1016\/S0021-9258(17)41845-X","article-title":"cDNA cloning and expression of rat and human protein geranylgeranyltransferase type-I","volume":"269","author":"Zhang","year":"1994","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtho.2024.11.022_bib32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/310583a0","article-title":"The p21 ras C-terminus is required for transformation and membrane association","volume":"310","author":"Willumsen","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.11.022_bib33","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1002\/j.1460-2075.1984.tb02177.x","article-title":"Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus","volume":"3","author":"Willumsen","year":"1984","journal-title":"EMBO J"},{"key":"10.1016\/j.jtho.2024.11.022_bib34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev.bi.65.070196.001325","article-title":"Protein prenylation: molecular mechanisms and functional consequences","volume":"65","author":"Zhang","year":"1996","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.jtho.2024.11.022_bib35","doi-asserted-by":"crossref","first-page":"14459","DOI":"10.1074\/jbc.272.22.14459","article-title":"K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors","volume":"272","author":"Whyte","year":"1997","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtho.2024.11.022_bib36","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/sj.onc.1201296","article-title":"Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines","volume":"15","author":"Lerner","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2024.11.022_bib37","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.onc.1201656","article-title":"Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts","volume":"16","author":"Sun","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2024.11.022_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106082","article-title":"Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers","volume":"26","author":"Tyc","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.jtho.2024.11.022_bib39","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1158\/1078-0432.CCR-10-2544","article-title":"Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice","volume":"17","author":"Balasis","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.11.022_bib40","doi-asserted-by":"crossref","first-page":"8433","DOI":"10.1158\/0008-5472.CAN-05-0158","article-title":"Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras","volume":"65","author":"Brunner","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2024.11.022_bib41","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1039\/b517572k","article-title":"Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I","volume":"4","author":"Peng","year":"2006","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.jtho.2024.11.022_bib42","doi-asserted-by":"crossref","first-page":"6930","DOI":"10.1074\/jbc.274.11.6930","article-title":"The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity","volume":"274","author":"Sun","year":"1999","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtho.2024.11.022_bib43","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.leukres.2013.07.034","article-title":"Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies","volume":"37","author":"Sampath","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.jtho.2024.11.022_bib44","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1158\/2767-9764.CRC-23-0222","article-title":"Discovery of KRB-456, a KRAS G12D Switch-I\/II allosteric pocket binder that inhibits the growth of pancreatic cancer patient-derived tumors","volume":"3","author":"Kazi","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.jtho.2024.11.022_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112570","article-title":"Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF\/MEK inhibition in melanoma","volume":"42","author":"Kim","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.jtho.2024.11.022_bib46","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jtho.2024.11.022_bib47","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2024.11.022_bib48","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-21-P05-01","article-title":"Abstract P05-01: a phase 1b study evaluating the safety and efficacy of sotorasib, a KRAS G12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-mutated solid tumors","volume":"20","author":"Ramalingam","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2024.11.022_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2022.07.022","article-title":"OA03.03 sotorasib in combination with RMC-4630, a SHP2 inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumors","volume":"17","author":"Falchook","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.11.022_bib50","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-21-P05-02","article-title":"Abstract P05-02: a phase 1b study evaluating the combination of sotorasib, a KRAS G12C inhibitor, and afatinib, a pan-ErbB tyrosine kinase inhibitor, in advanced KRAS p.G12C mutated non-small cell lung cancer (NSCLC)","volume":"20","author":"Gandara","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2024.11.022_bib51","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","article-title":"Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy","volume":"629","author":"Holderfield","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.11.022_bib52","doi-asserted-by":"crossref","first-page":"S458","DOI":"10.1016\/j.annonc.2023.09.1838","article-title":"652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)","volume":"34","author":"Arbour","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.11.022_bib53","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1021\/jm1001748","article-title":"Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents","volume":"53","author":"Fletcher","year":"2010","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jtho.2024.11.022_bib54","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ajpath.2015.01.016","article-title":"Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements","volume":"185","author":"Delitto","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jtho.2024.11.022_bib55","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J\u00a0R Stat Soc Series B Stat Methodol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424024857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424024857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:27:57Z","timestamp":1762550877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086424024857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1556086424024857"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2024.11.022","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2024.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}